Christopher M. Riley, President of Riley and Rabel Consulting Services Inc., will be giving a two-part seminar titled “HPLC is the Worst Technique for Quantitative Analysis of Drugs and Drug Impurities – Except All Others: Determination of Vancomycin Impurities in Dry Powder Inhalation Product – An Example! âFrom 3 pm to 5 pm on Friday, November 19. Everyone is welcome to attend the seminar via Zoom or in person at CHEM 144. The conference is free and open to the public.
Riley is the President and Co-Founder of Riley and Rabel Consulting Services Inc. Riley received his Bachelor of Pharmacy (1977) and Doctorate degrees. degree in Pharmaceutical Chemistry (1980) from the University of Bath, England. He was a postdoctoral fellow at the University of Kansas in the Department of Pharmaceutical Chemistry (1981-1982) before joining the faculty of the Department of Pharmacy at the University of Florida. He returned to the University of Kansas as a faculty member in 1986, where he remained until 1994.
Riley’s industrial experience began in 1994 as head of analytical R&D at Dupont Pharmaceuticals (formerly Dupont Merck). In late 2001, he joined ALZA, a subsidiary of Johnson & Johnson, where he held positions of increasing responsibility to Vice President and West Coast Site Manager of ChemPharm Development. He left ALZA in May 2007 to form Riley and Rabel Consulting Services. He is the co-author of over 100 book chapters and peer-reviewed journal articles, as well as two books titled Pharmaceutical and biomedical applications of liquid chromatography and Validation of methods and systems in pharmaceutical and biomedical analysis. He was elected a Fellow of the American Association of Pharmaceutical Scientists (AAPS) and served as Chairman of the Analysis and Pharmaceutical Quality section of AAPS and a member of the AAPS Executive Committee. Riley has served as a member and chairman of the PhRMA Analytical Technical Committee, as well as a member and chairman of the PhRMA Technical Steering Committee. Riley represented PhRMA on the ICH Expert Working Group on Impurities in Drug Substances (Q3A) and Pharmaceuticals (Q3B) and chaired the PhRMA Working Group on Genotoxic Impurities.
Starting at 3 p.m., the first part will be an informal discussion on some of the requirements for analytical methods in a regulated industry, in this case the requirements for analytical methods used in the development and commercialization of new drugs. At 4 p.m., Riley will give a presentation on the development and validation of a method for determining impurities in vancomycin and the problems caused by the loss of separation of three critical pairs of peaks after almost two years of use and analysis. thousands of samples.
To virtually attend the seminar, please visit the Zoom link.
Meeting number: 870 1464 3915
Password: jq8WX = Dg